EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Pembrolizumab-associated immune-related hepatitis: a retrospective case report analysis

Ke-Qian Chen, Yang Chen, Jing-Fu Peng, Yi Huang, Xiang Liu

Frontiers in Medicine · 17.06.2026 · 13

DOI: 10.3389/fmed.2026.1823347 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Medicine, online erschienen am 17.06.2026. Verfasst von Ke-Qian Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Xiangtan Central Hospital, The Affiliated Hospital of Hunan University, Xiangtan, China. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Analyzing the clinical characteristics, potential mechanisms, and treatment strategies of pembrolizumab-induced immune-related hepatitis to improve clinical management and treatment safety.

Methods

Case reports on pembrolizumab-induced immune-related hepatitis were retrieved from databases including PubMed, Science Direct, and Web of Science. Forty-two case reports were carefully reviewed and data on patient age, gender, primary disease, time to hepatitis onset, clinical manifestations, liver injury indicators, adverse reaction grading, treatment strategies, and prognosis were collected and analyzed.

Results

Among these patients, 27 were male and 14 were female, and the average age was 64.2 years. The clinical manifestations included liver toxicity, neurological symptoms, skin reactions, systemic symptoms, and digestive symptoms. The time from initiation of pembrolizumab to the onset of immune-related hepatitis varied significantly. The shortest duration is 2 days, while the longest is 630 days. Corticosteroids were the primary treatment. The pathogenesis may be related to the dysregulation of liver immune tolerance.

Conclusion

Before initiating pembrolizumab, clinicians should thoroughly evaluate patients' liver function and history of liver disease, and consider the hepatotoxicity of concurrent medications. During the use of pembrolizumab, regular monitoring of liver function should be conducted. If any abnormalities are found, appropriate treatment should be given promptly. Meanwhile, further research is needed to better understand pembrolizumab-induced immune-related hepatitis.

Schlagwörter

Stichwörter der Autor:innen

PD-1 inhibitorsimmune checkpoint inhibitorsimmune-related adverse eventsimmune-related hepatitispembrolizumab

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, Xiangtan Central Hospital, The Affiliated Hospital of Hunan University, Xiangtan, China.
  • Department of Clinical Pharmacy, The First People's Hospital of Loudi, Loudi, China.
  • College of Pharmacy, Shaoyang Polytechnic, Shaoyang, China.

Zitieren

APA

Chen, K. Q., Chen, Y., Peng, J. F., Huang, Y., & Liu, X. (2026). Pembrolizumab-associated immune-related hepatitis: a retrospective case report analysis. Frontiers in Medicine, 13. https://doi.org/10.3389/fmed.2026.1823347

Vancouver

Chen KQ, Chen Y, Peng JF, Huang Y, Liu X. Pembrolizumab-associated immune-related hepatitis: a retrospective case report analysis. Frontiers in Medicine. 2026;13. doi:10.3389/fmed.2026.1823347

BibTeX
@article{Chen2026,
  author = {Chen, Ke-Qian and Chen, Yang and Peng, Jing-Fu and Huang, Yi and Liu, Xiang},
  title = {Pembrolizumab-associated immune-related hepatitis: a retrospective case report analysis},
  journal = {Frontiers in Medicine},
  year = {2026},
  volume = {13},
  doi = {10.3389/fmed.2026.1823347}
}
Kostenlos starten →